First Patient Enrolled in Ph 1 Trial of Tumor-Associated Antigen Cancer Vaccine EVM14 October 21, 2025
First patients enrolled in Ph 1 trial with KQB548 (BAY 3771249) in KRAS G12D-mutated tumors October 21, 2025
Ivonescimab Global Ph 3 Development Program with HARMONi-GI3 Study expanded in 1L CRC October 21, 2025
Ph 2 study of BND-22 (SAR444881) + anti-PD-1 therapy in IO-refractory NSCLC or IO-naive MSS-CRC or ovarian cancer to be initiated October 16, 2025
Initiation of Ph 1/2 study of AVZO-103 in patients with advanced solid tumors announced October 8, 2025
First Patient Enrolled in TRUST-IV Ph 3 Study of IBTROZI™ (taletrectinib) for the Adjuvant Treatment of Early-Stage ROS1+ve NSCLC October 8, 2025
Initial clinical data for BDC-4182 Ph 1 dose escalation study now expected in 3Q 2026 October 7, 2025
First patient with follicular lymphoma (FL) dosed in CELESTIAL-301 Ph 1 trial of SynKIR™-310 October 4, 2025
Investigator-Initiated Ph 1 Trial for Neoadjuvant ELI-002 7P in Pancreatic Ductal Adenocarcinoma planned September 30, 2025
THIO-101 Ph 2 trial to enroll patients in the U.S. as part of the expansion of the study in 3L treatment for advanced NSCLC September 30, 2025
ACT appointed for POLB 001 Ph 2a Trial and supply of approved bispecific antibody drug secured at no cost September 30, 2025
First patient dosed in Ph 1/2 Dose Escalation & Expansion Trial of CP-383 in Advanced Solid Tumors September 23, 2025
Tinostamustine included in Ph 2/3 GBM AGILE adaptive clinical trial for GBM patients September 23, 2025
Initial patients dosed in multiple cohorts of Ph 1 dose-expansion study of KTX-1001, mezigdomide, and SoC combo in t(4;14) multiple myeloma September 23, 2025
First Patient Dosed in Ph 2 Study of AK130 + Ivonescimab for Advanced Pancreatic Cancer September 23, 2025
Enrollment completed in Ph 2 Combi-TED Trial of Tedopi® in Combination with Nivolumab or Docetaxel in Patients with NSCLC September 16, 2025
Enrollment of Ph 1 TRE-515 Dose Escalation Trial for Patients with Solid Tumors Completed September 16, 2025
First Patient Dosed in Global Registrational Trial of Cadonilimab for PD-1 Treatment-Resistant HCC September 16, 2025
First patient dosed in trial of huCART19-IL18 cells in the treatment of heme cancers September 10, 2025
Ph 3 PiNACLE – H2H of rondecabtagene autoleucel (ronde-cel, aka LYL314) vs liso-cel or axi-cel initiated in R/R LBCL September 9, 2025
